CD274 and non-small cell lung carcinoma: Tremelimumab has since been assessed in clinical trials for the treatment of mesothelioma, melanoma, liver cancer, bladder cancer, NSCLC, pancreatic cancer, prostate cancer, renal cancer, urogenital cancer and head and neck cancers as well as in combination with PD-L1 inhibitors [291].